ClinicalTrials.gg
CompletedNCT00963235Updated Jun 10, 2013Results posted

Safety & Immunogenicity of 13vPnC in HIV-Infected Subjects Aged 18 or Older Who Were Previously Immunized With 23vPS

A Phase 3 interventional study of 13-valent pneumococcal conjugate vaccine and Blood draw in HIV Infections and Pneumococcal Infections, sponsored by Pfizer. Completed at 15 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-06-10.

Sponsored by Pfizer · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
331
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 65 studies in HIV Infections by Pfizer — none open to participants now, none under way, none of them phase 3. HIV Infections · Pfizer.

Enrollment
6th of 28
331 · median 160
Started
2009
with 2 others
Phase 3
10 of 65
none open now
Registered
64th of 65
by date

Among the 65 studies in HIV Infections by Pfizer, this one is the 6th largest by enrollment of the 28 interventional ones that give a count, is one of 3 that started in 2009, is one of 10 in phase 3, and was the 64th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

None of the 65 studies in HIV Infections by Pfizer is open now. The open studies under HIV Infections, anywhere →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 65 studies in HIV Infections by Pfizer as a file.
02

Study summary

The study will evaluate the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate vaccine (13vPnC) in HIV-infected subjects 18 years of age or older who have been previously immunized with at least one dose of 23-valent pneumococcal polysaccharide vaccine (23vPS). All subjects will receive 3 doses of 13vPnC, with each study vaccine dose given approximately 6 months apart.

03

Conditions studied

  • HIV Infections
  • Pneumococcal Infections

Keywords

  • vaccine
  • 13-valent pneumococcal conjugate vaccine
  • human immunodeficiency virus
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects aged 18 years or older at the time of enrollment.
  • All female and male subjects who are biologically capable of having children must agree and commit to the use of a reliable method of from the signing of the form (ICF) until 3 months after the last dose of product.
  • Documented vaccination with 1 or more doses of 23vPS at least 6 months before study enrollment.
  • >= 200 cells/µ, obtained on the most recent 2 occasions within 6 months before the first investigational product vaccination.
  • -infected subjects with viral load \<50,000 copies/mL, obtained on the most recent 2 occasions within 6 months before the first investigational product vaccination.
  • Subject is receiving a stable dose of HAART for at least 6 weeks prior to the first investigational product vaccination, or not currently receiving antiretroviral therapy.
  • Subject is expected to be available for the entire study period (approximately 18 months) and can be contacted by telephone.
  • Subject must be able to complete an electronic diary (e-diary) and complete all relevant study procedures during study participation.
  • Subject is deemed to be eligible for the study on the basis of medical history, physical examination, and clinical judgment. (Note: Subjects with preexisting stable disease, defined as disease not requiring significant change in therapy or hospitalization for worsening disease 6 weeks before investigational product vaccination, are eligible.)

Exclusion criteria

Exclusion Criteria:

  • Subjects with active AIDS related illness, including opportunistic infections or .
  • Evidence of current illicit substance and/or alcohol abuse, that in the investigator's opinion, precludes the subject from participating in the study or interferes with the evaluation of the study objectives..
  • Receipt of any licensed or experimental pneumococcal conjugate vaccine prior to enrollment.
  • to vaccination with pneumococcal conjugate vaccine.
  • Previous anaphylactic reaction to any vaccine or vaccine-related component.
  • History of culture-proven invasive disease caused by Streptococcus pneumoniae within the last year.
  • Current anticoagulant therapy or a history of bleeding diathesis or any condition associated with prolonged bleeding time that would contraindicate intramuscular injection. (Note: Use of antiplatelet drugs, such as aspirin and clopidogrel, is permitted.)
  • Pregnant or breastfeeding women, as defined by history or positive human chorionic gonadotropin (hCG) urine test. All women of must have a urine pregnancy test.
  • History of active hepatitis with elevation in pretreatment (AST) or alanine aminotransferase (ALT) values >5 times the within the last 6 months.
  • Serious chronic disorder or any other disorder that, in the investigator's opinion, precludes the subject from participating in the study or interferes with the evaluation of the study objectives. (Note: Serious chronic disorders include malignancy, severe requiring supplemental oxygen, end-stage renal disease with or without dialysis, and clinically unstable cardiac disease).
  • Any major illness/condition that, in the investigator's judgment, will substantially increase the risk associated with the subject's participation in and completion of, the study, or could preclude the evaluation of the subject's response.
  • History of splenectomy.
  • Receipt of any blood products, including immunoglobulin, within 42 days before product vaccination until the last blood draw for the study (approximately 13 months after the first investigational product vaccination).
  • Evidence of dementia or other severe cognitive impairment.
  • Subject who is, in the opinion of the investigator, unable to receive a vaccination in the deltoid muscle of either arm because of insufficient muscle mass.
  • Participation in another study using investigational product from 28 days before study enrollment until the blood draw at visit 6. Between the blood draw at visit 6 and the 6 month follow-up telephone call (visit 7), use of investigational product must be discussed with the Medical Monitor. (Note: Participation in purely observational studies is acceptable.)
  • Residence in a nursing home, long-term care facility, or other institution or requirement of semi-skilled nursing care. An ambulatory resident of a retirement home or village is eligible for the trial.
  • Subject who is a direct relative (child, grandchild, parent, or grandparent) of study personnel, or who is study personnel.

Temporary Delay Criteria:

  • Current febrile illness (oral temperature of =38.0°C [100.4°F]) or other acute illness within 48 hours before study vaccine administration.
  • Currently receiving antibiotic therapy, or has completed a course of antibiotic therapy within 10 days before study vaccine administration.
  • Receipt of novel influenza A (H1N1) vaccine within 14 days before investigational product vaccination (seasonal influenza vaccine can be given at any time at the discretion of the investigator).
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
331 participants (actual)

Study arms

  • Experimental
    1

    Biological: 13-valent pneumococcal conjugate vaccine · Procedure: Blood draw

Interventions

  • Three doses of 13vPnC given 6 months apart.

    Also known as: 13vPnC

  • ProcedureBlood draw

    Six blood draws pre-vaccination and 1 month post-vaccination, doses 1-3.

06

What researchers measure

Primary outcomes

  1. Geometric Mean Fold Rise (GMFR) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody From 1 Month After Dose 2 of 13vPnC to 1 Month After Dose 3 of 13vPnC

    Geometric mean fold rises (GMFRs) for the 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from 1 month post-dose 2 to 1 month post-dose 3 were computed using the logarithmically transformed assay results. Confidence interval (CI) for the GMFRs were back transformations of a CI based on the Student t distribution for the logarithmically transformed assay results.

    Time frame: 1 month post-dose 2, 1 month post-dose 3

Secondary outcomes

  1. Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After Dose 3 of 13vPnC Relative to 1 Month After Dose 2 of 13vPnC

    Antibody GMC for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were presented. GMC (13vPnC) and corresponding 2-sided 95 percent (%) CIs were evaluated. Geometric means (GMs) were calculated using all participants with available data for both post-dose 2 and post-dose 3 blood draws.

    Time frame: 1 month post-dose 2, 1 month post-dose 3

  2. Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After Dose 2 of 13vPnC Relative to 1 Month After Dose 1 of 13vPnC

    Antibody GMC for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were presented. GMC (13vPnC) and corresponding 2-sided 95% CI were evaluated. GMs were calculated using all participants with available data for both post-dose 1 and post-dose 2 blood draws.

    Time frame: 1 month post-dose 1, 1 month post-dose 2

  3. Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) 1 Month After Dose 3 of 13vPnC Relative to 1 Month After Dose 2 of 13vPnC

    Serotype-specific OPA GMTs for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in the blood samples of all the participants using a microcolony OPA (mcOPA) assay. GMT (13vPnC) and corresponding 2-sided 95% CI were evaluated. GMs were calculated using all participants with available data for both post-dose 2 and post-dose 3 blood draws.

    Time frame: 1 month post-dose 2, 1 month post-dose 3

  4. Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) 1 Month After Dose 2 of 13vPnC Relative to 1 Month After Dose 1 of 13vPnC

    Serotype-specific OPA GMTs for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in the blood samples of all the participants using a microcolony OPA (mcOPA) assay. GMT (13vPnC) and corresponding 2-sided 95% CI were evaluated. GMs were calculated using all participants with available data for both post-dose 2 and post-dose 3 blood draws.

    Time frame: 1 month post-dose 1, 1 month post-dose 2

  5. Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Fold Rise (GMFR) From 1 Month After Dose 2 of 13vPnC to 1 Month After Dose 3 of 13vPnC

    GMFRs for the 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from 1 month post-dose 2 to 1 month post-dose 3 were computed using the logarithmically transformed assay results. CI for the GMFRs were back transformations of a CI based on the Student t distribution for the logarithmically transformed assay results.

    Time frame: 1 month post-dose 2, 1 month post-dose 3

  6. Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Fold Rise (GMFR) From 1 Month After Dose 1 of 13vPnC to 1 Month After Dose 2 of 13vPnC

    GMFRs for the 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from 1 month post-dose 1 to 1 month post-dose 2 were computed using the logarithmically transformed assay results. CI for the GMFRs were back transformations of a CI based on the Student t distribution for the logarithmically transformed assay results.

    Time frame: 1 month post-dose 1, 1 month post-dose 2

Other outcomes

  1. Percentage of Participants Reporting Pre-Specified Local Reactions: 13vPnC Dose 1

    Specific local reactions were prompted for each day, and reported using an electronic diary. Redness and Swelling scaled as Any (redness present or swelling present); Mild (2.5 to 5.0 centimeters \[cm\]); Moderate (5.5 to 10.0 cm); Severe (greater than \[\>\] 10 cm). Pain scaled as Any (pain present); Mild (awareness of pain; easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating).

    Time frame: Within 14 days post-dose 1

  2. Percentage of Participants Reporting Pre-Specified Local Reactions: 13vPnC Dose 2

    Specific local reactions were prompted for each day, and reported using an electronic diary. Redness and Swelling scaled as Any (redness present or swelling present); Mild (2.5 to 5.0 cm); Moderate (5.5 to 10.0 cm); Severe (\>10 cm). Pain scaled as Any (pain present); Mild (awareness of pain; easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating).

    Time frame: Within 14 days post-dose 2

  3. Percentage of Participants Reporting Pre-Specified Local Reactions: 13vPnC Dose 3

    Specific local reactions were prompted for each day, and reported using an electronic diary. Redness and Swelling scaled as Any (redness present or swelling present); Mild (2.5 to 5.0 cm); Moderate (5.5 to 10.0 cm); Severe (\>10 cm). Pain scaled as Any (pain present); Mild (awareness of pain; easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating).

    Time frame: Within 14 days post-dose 3

  4. Percentage of Participants Reporting Pre-Specified Systemic Events: 13vPnC Dose 1

    Specific systemic events (fever greater than or equal to \[\>=\]38 degrees Celsius\[C\], fatigue, headache, vomiting, diarrhea, new generalized muscle/joint pain and use of medication to treat pain/fever) were prompted for each day, and reported using an electronic diary. Fatigue, headache, new generalized muscle and joint pain were scaled as: Any (symptom present); Mild (no interference with activity); Moderate (some interference); Severe (prevents routine daily activity). Vomiting was scaled as: Any (vomiting present); Mild (1-2 times in 24 hours \[hrs\]); Moderate (\>2 times in 24 hrs); Severe (requires intravenous hydration). Diarrhea was scaled as: Any (diarrhea present); Mild (2-3 loose stools in 24 hrs); Moderate (4-5 loose stools 24 hrs); Severe (\>=6 loose stools in 24 hrs). Report of fever \>40 degrees C after 13vPnC Dose 1 was confirmed as data entry error.

    Time frame: Within 14 days post-dose 1

  5. Percentage of Participants Reporting Pre-Specified Systemic Events: 13vPnC Dose 2

    Specific systemic events (fever \>=38 degrees C, fatigue, headache, vomiting, diarrhea, new generalized muscle/joint pain and use of medication to treat pain/fever) were prompted for each day, and reported using an electronic diary. Fatigue, headache, new generalized muscle and joint pain were scaled as: Any (symptom present); Mild (no interference with activity); Moderate (some interference); Severe (prevents routine daily activity). Vomiting was scaled as: Any (vomiting present); Mild (1-2 times in 24 hrs); Moderate (\>2 times in 24 hrs); Severe (requires intravenous hydration). Diarrhea was scaled as: Any (diarrhea present); Mild (2-3 loose stools in 24 hrs); Moderate (4-5 loose stools 24 hrs); Severe (\>=6 loose stools in 24 hrs).

    Time frame: Within 14 days post-dose 2

  6. Percentage of Participants Reporting Pre-Specified Systemic Events: 13vPnC Dose 3

    Specific systemic events (fever \>=38 degrees C, fatigue, headache, vomiting, diarrhea, new generalized muscle/joint pain and use of medication to treat pain/fever) were prompted for each day, and reported using an electronic diary. Fatigue, headache, new generalized muscle and joint pain were scaled as: Any (symptom present); Mild (no interference with activity); Moderate (some interference); Severe (prevents routine daily activity). Vomiting was scaled as: Any (vomiting present); Mild (1-2 times in 24 hrs); Moderate (\>2 times in 24 hrs); Severe (requires intravenous hydration). Diarrhea was scaled as: Any (diarrhea present); Mild (2-3 loose stools in 24 hrs); Moderate (4-5 loose stools 24 hrs); Severe (\>=6 loose stools in 24 hrs).

    Time frame: Within 14 days post-dose 3

07

Results

Posted Jun 10, 2013

Participant flow

Participant flow — Overall Study
Milestone13vPnC
Started331
Vaccinated dose 1329
Vaccinated dose 2300
Vaccinated dose 3279
Completed dose 3 1-month blood draw277
Completed271
Not completed60
Withdrew: Withdrawal by subject22
Withdrew: Lost to follow-up14
Withdrew: Failed to return9
Withdrew: Protocol violation7
Withdrew: Adverse event5
Withdrew: Physician decision2
Withdrew: Other1

Outcome measures

PrimaryGeometric Mean Fold Rise (GMFR) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody From 1 Month After Dose 2 of 13vPnC to 1 Month After Dose 3 of 13vPnC

Geometric mean fold rises (GMFRs) for the 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from 1 month post-dose 2 to 1 month post-dose 3 were computed using the logarithmically transformed assay results. Confidence interval (CI) for the GMFRs were back transformations of a CI based on the Student t distribution for the logarithmically transformed assay results.

Time frame:
1 month post-dose 2, 1 month post-dose 3
Reported as:
Geometric mean · fold rise
Geometric Mean Fold Rise (GMFR) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody From 1 Month After Dose 2 of 13vPnC to 1 Month After Dose 3 of 13vPnC
fold rise13vPnC
Serotype 10.94 (0.88 to 1.01)
Serotype 31.01 (0.95 to 1.08)
Serotype 41.01 (0.94 to 1.08)
Serotype 50.99 (0.94 to 1.05)
Serotype 6A1.19 (1.11 to 1.27)
Serotype 6B1.21 (1.13 to 1.31)
Serotype 7F1.07 (1.00 to 1.14)
Serotype 9V1.08 (1.02 to 1.15)
Serotype 141.08 (0.99 to 1.17)
Serotype 18C1.09 (1.02 to 1.16)
Serotype 19A1.03 (0.98 to 1.09)
Serotype 19F1.17 (1.08 to 1.27)
Serotype 23F1.25 (1.15 to 1.37)
SecondaryGeometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After Dose 3 of 13vPnC Relative to 1 Month After Dose 2 of 13vPnC

Antibody GMC for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were presented. GMC (13vPnC) and corresponding 2-sided 95 percent (%) CIs were evaluated. Geometric means (GMs) were calculated using all participants with available data for both post-dose 2 and post-dose 3 blood draws.

Time frame:
1 month post-dose 2, 1 month post-dose 3
Reported as:
Geometric mean · microgram per milliliter (mcg/mL)
Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After Dose 3 of 13vPnC Relative to 1 Month After Dose 2 of 13vPnC
microgram per milliliter (mcg/mL)13vPnC
Serotype 1: Dose 22.31 (1.97 to 2.72)
Serotype 1: Dose 32.18 (1.88 to 2.54)
Serotype 3: Dose 20.54 (0.47 to 0.62)
Serotype 3: Dose 30.55 (0.47 to 0.63)
Serotype 4: Dose 21.62 (1.41 to 1.87)
Serotype 4: Dose 31.63 (1.42 to 1.88)
Serotype 5: Dose 23.26 (2.79 to 3.80)
Serotype 5: Dose 33.23 (2.78 to 3.75)
Serotype 6A: Dose 23.86 (3.20 to 4.66)
Serotype 6A: Dose 34.60 (3.85 to 5.50)
Serotype 6B: Dose 24.49 (3.70 to 5.46)
Serotype 6B: Dose 35.45 (4.53 to 6.57)
Serotype 7F: Dose 23.40 (2.95 to 3.92)
Serotype 7F: Dose 33.62 (3.17 to 4.14)
Serotype 9V: Dose 22.95 (2.56 to 3.41)
Serotype 9V: Dose 33.20 (2.79 to 3.66)
Serotype 14: Dose 27.57 (6.27 to 9.15)
Serotype 14: Dose 38.16 (6.87 to 9.69)
Serotype 18C: Dose 22.75 (2.33 to 3.24)
Serotype 18C: Dose 32.99 (2.56 to 3.50)
Serotype 19A: Dose 27.57 (6.54 to 8.76)
Serotype 19A: Dose 37.80 (6.82 to 8.93)
Serotype 19F: Dose 25.73 (4.73 to 6.95)
Serotype 19F: Dose 36.70 (5.61 to 8.01)
Serotype 23F: Dose 23.80 (3.17 to 4.57)
Serotype 23F: Dose 34.77 (4.01 to 5.67)
SecondaryGeometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After Dose 2 of 13vPnC Relative to 1 Month After Dose 1 of 13vPnC

Antibody GMC for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were presented. GMC (13vPnC) and corresponding 2-sided 95% CI were evaluated. GMs were calculated using all participants with available data for both post-dose 1 and post-dose 2 blood draws.

Time frame:
1 month post-dose 1, 1 month post-dose 2
Reported as:
Geometric mean · mcg/mL
Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After Dose 2 of 13vPnC Relative to 1 Month After Dose 1 of 13vPnC
mcg/mL13vPnC
Serotype 1: Dose 12.15 (1.80 to 2.57)
Serotype 1: Dose 22.36 (2.03 to 2.75)
Serotype 3: Dose 10.48 (0.41 to 0.56)
Serotype 3: Dose 20.57 (0.49 to 0.65)
Serotype 4: Dose 11.37 (1.15 to 1.64)
Serotype 4: Dose 21.64 (1.43 to 1.89)
Serotype 5: Dose 12.90 (2.48 to 3.40)
Serotype 5: Dose 23.29 (2.83 to 3.81)
Serotype 6A: Dose 12.80 (2.28 to 3.43)
Serotype 6A: Dose 23.86 (3.23 to 4.62)
Serotype 6B: Dose 12.90 (2.36 to 3.57)
Serotype 6B: Dose 24.47 (3.72 to 5.38)
Serotype 7F: Dose 13.45 (2.91 to 4.11)
Serotype 7F: Dose 23.41 (2.99 to 3.90)
Serotype 9V: Dose 12.63 (2.25 to 3.07)
Serotype 9V: Dose 22.99 (2.62 to 3.42)
Serotype 14: Dose 16.18 (4.97 to 7.68)
Serotype 14: Dose 27.60 (6.35 to 9.09)
Serotype 18C: Dose 12.87 (2.37 to 3.48)
Serotype 18C: Dose 22.68 (2.29 to 3.13)
Serotype 19A: Dose 16.53 (5.54 to 7.69)
Serotype 19A: Dose 27.63 (6.65 to 8.74)
Serotype 19F: Dose 12.75 (2.18 to 3.49)
Serotype 19F: Dose 25.70 (4.75 to 6.84)
Serotype 23F: Dose 12.62 (2.11 to 3.25)
Serotype 23F: Dose 23.82 (3.21 to 4.56)
SecondarySerotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) 1 Month After Dose 3 of 13vPnC Relative to 1 Month After Dose 2 of 13vPnC

Serotype-specific OPA GMTs for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in the blood samples of all the participants using a microcolony OPA (mcOPA) assay. GMT (13vPnC) and corresponding 2-sided 95% CI were evaluated. GMs were calculated using all participants with available data for both post-dose 2 and post-dose 3 blood draws.

Time frame:
1 month post-dose 2, 1 month post-dose 3
Reported as:
Geometric mean · titers
Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) 1 Month After Dose 3 of 13vPnC Relative to 1 Month After Dose 2 of 13vPnC
titers13vPnC
Serotype 1: Dose 241 (32.6 to 50.9)
Serotype 1: Dose 349 (40.1 to 61.0)
Serotype 3: Dose 244 (36.9 to 52.4)
Serotype 3: Dose 356 (47.5 to 66.3)
Serotype 4: Dose 2703 (567.6 to 870.5)
Serotype 4: Dose 3724 (585.2 to 896.6)
Serotype 5: Dose 267 (51.9 to 86.1)
Serotype 5: Dose 374 (57.6 to 94.2)
Serotype 6A: Dose 21780 (1392.7 to 2274.5)
Serotype 6A: Dose 32139 (1709.0 to 2678.3)
Serotype 6B: Dose 21857 (1509.8 to 2284.3)
Serotype 6B: Dose 32447 (2011.9 to 2977.3)
Serotype 7F: Dose 2942 (778.6 to 1139.6)
Serotype 7F: Dose 31041 (846.5 to 1279.4)
Serotype 9V: Dose 2657 (482.7 to 893.4)
Serotype 9V: Dose 3922 (696.0 to 1221.7)
Serotype 14: Dose 2746 (614.8 to 905.8)
Serotype 14: Dose 3819 (684.7 to 978.8)
Serotype 18C: Dose 2521 (383.9 to 706.2)
Serotype 18C: Dose 3692 (516.2 to 927.7)
Serotype 19A: Dose 2401 (340.2 to 473.0)
Serotype 19A: Dose 3419 (358.2 to 490.5)
Serotype 19F: Dose 2269 (202.3 to 357.3)
Serotype 19F: Dose 3245 (184.2 to 325.8)
Serotype 23F: Dose 2293 (217.2 to 395.0)
Serotype 23F: Dose 3393 (295.0 to 522.7)
SecondarySerotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) 1 Month After Dose 2 of 13vPnC Relative to 1 Month After Dose 1 of 13vPnC

Serotype-specific OPA GMTs for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in the blood samples of all the participants using a microcolony OPA (mcOPA) assay. GMT (13vPnC) and corresponding 2-sided 95% CI were evaluated. GMs were calculated using all participants with available data for both post-dose 2 and post-dose 3 blood draws.

Time frame:
1 month post-dose 1, 1 month post-dose 2
Reported as:
Geometric mean · titers
Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) 1 Month After Dose 2 of 13vPnC Relative to 1 Month After Dose 1 of 13vPnC
titers13vPnC
Serotype 1: Dose 140 (32.2 to 50.2)
Serotype 1: Dose 240 (32.6 to 49.7)
Serotype 3: Dose 129 (24.0 to 34.9)
Serotype 3: Dose 243 (36.4 to 51.4)
Serotype 4: Dose 1622 (478.8 to 806.9)
Serotype 4: Dose 2695 (568.1 to 850.7)
Serotype 5: Dose 166 (51.2 to 85.7)
Serotype 5: Dose 265 (50.8 to 82.1)
Serotype 6A: Dose 1976 (710.3 to 1342.0)
Serotype 6A: Dose 21687 (1317.2 to 2159.5)
Serotype 6B: Dose 11088 (806.0 to 1468.4)
Serotype 6B: Dose 21789 (1443.4 to 2216.8)
Serotype 7F: Dose 1786 (606.6 to 1018.0)
Serotype 7F: Dose 2927 (763.6 to 1125.2)
Serotype 9V: Dose 1423 (300.6 to 594.1)
Serotype 9V: Dose 2695 (518.3 to 932.0)
Serotype 14: Dose 1640 (509.2 to 805.7)
Serotype 14: Dose 2723 (602.4 to 867.2)
Serotype 18C: Dose 1475 (338.5 to 665.5)
Serotype 18C: Dose 2562 (421.7 to 748.9)
Serotype 19A: Dose 1299 (239.7 to 372.2)
Serotype 19A: Dose 2391 (333.2 to 458.6)
Serotype 19F: Dose 1132 (93.6 to 185.0)
Serotype 19F: Dose 2247 (189.3 to 322.9)
Serotype 23F: Dose 192 (65.6 to 127.9)
Serotype 23F: Dose 2269 (201.3 to 360.7)
SecondarySerotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Fold Rise (GMFR) From 1 Month After Dose 2 of 13vPnC to 1 Month After Dose 3 of 13vPnC

GMFRs for the 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from 1 month post-dose 2 to 1 month post-dose 3 were computed using the logarithmically transformed assay results. CI for the GMFRs were back transformations of a CI based on the Student t distribution for the logarithmically transformed assay results.

Time frame:
1 month post-dose 2, 1 month post-dose 3
Reported as:
Geometric mean · fold rise
Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Fold Rise (GMFR) From 1 Month After Dose 2 of 13vPnC to 1 Month After Dose 3 of 13vPnC
fold rise13vPnC
Serotype 11.2 (1.06 to 1.39)
Serotype 31.3 (1.13 to 1.44)
Serotype 41.0 (0.90 to 1.18)
Serotype 51.1 (0.95 to 1.28)
Serotype 6A1.2 (1.04 to 1.39)
Serotype 6B1.3 (1.16 to 1.50)
Serotype 7F1.1 (0.95 to 1.28)
Serotype 9V1.4 (1.09 to 1.81)
Serotype 141.1 (0.97 to 1.24)
Serotype 18C1.3 (1.10 to 1.60)
Serotype 19A1.0 (0.95 to 1.15)
Serotype 19F0.9 (0.76 to 1.09)
Serotype 23F1.3 (1.16 to 1.56)
SecondarySerotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Fold Rise (GMFR) From 1 Month After Dose 1 of 13vPnC to 1 Month After Dose 2 of 13vPnC

GMFRs for the 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from 1 month post-dose 1 to 1 month post-dose 2 were computed using the logarithmically transformed assay results. CI for the GMFRs were back transformations of a CI based on the Student t distribution for the logarithmically transformed assay results.

Time frame:
1 month post-dose 1, 1 month post-dose 2
Reported as:
Geometric mean · fold rise
Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Fold Rise (GMFR) From 1 Month After Dose 1 of 13vPnC to 1 Month After Dose 2 of 13vPnC
fold rise13vPnC
Serotype 11.0 (0.84 to 1.20)
Serotype 31.5 (1.29 to 1.73)
Serotype 41.1 (0.92 to 1.36)
Serotype 51.0 (0.79 to 1.20)
Serotype 6A1.7 (1.39 to 2.15)
Serotype 6B1.6 (1.34 to 2.02)
Serotype 7F1.2 (0.96 to 1.45)
Serotype 9V1.6 (1.26 to 2.14)
Serotype 141.1 (0.98 to 1.30)
Serotype 18C1.2 (0.95 to 1.47)
Serotype 19A1.3 (1.15 to 1.50)
Serotype 19F1.9 (1.48 to 2.39)
Serotype 23F2.9 (2.29 to 3.77)
Other pre-specifiedPercentage of Participants Reporting Pre-Specified Local Reactions: 13vPnC Dose 1

Specific local reactions were prompted for each day, and reported using an electronic diary. Redness and Swelling scaled as Any (redness present or swelling present); Mild (2.5 to 5.0 centimeters \[cm\]); Moderate (5.5 to 10.0 cm); Severe (greater than \[\>\] 10 cm). Pain scaled as Any (pain present); Mild (awareness of pain; easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating).

Time frame:
Within 14 days post-dose 1
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Pre-Specified Local Reactions: 13vPnC Dose 1
percentage of participants13vPnC
Redness: any (n = 162)5.6 (2.6 to 10.3)
Redness: mild (n = 161)4.3 (1.8 to 8.8)
Redness: moderate (n = 158)1.3 (0.2 to 4.5)
Redness: severe (n = 157)0.0 (0.0 to 2.3)
Swelling: any (n = 162)6.8 (3.4 to 11.8)
Swelling: mild (n = 161)6.2 (3.0 to 11.1)
Swelling: moderate (n = 158)0.6 (0.0 to 3.5)
Swelling: severe (n = 158)0.6 (0.0 to 3.5)
Pain: any (n = 260)78.8 (73.4 to 83.6)
Pain: mild (n = 258)76.4 (70.7 to 81.4)
Pain: moderate (n = 173)18.5 (13.0 to 25.1)
Pain: severe (n = 158)1.3 (0.2 to 4.5)
Other pre-specifiedPercentage of Participants Reporting Pre-Specified Local Reactions: 13vPnC Dose 2

Specific local reactions were prompted for each day, and reported using an electronic diary. Redness and Swelling scaled as Any (redness present or swelling present); Mild (2.5 to 5.0 cm); Moderate (5.5 to 10.0 cm); Severe (\>10 cm). Pain scaled as Any (pain present); Mild (awareness of pain; easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating).

Time frame:
Within 14 days post-dose 2
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Pre-Specified Local Reactions: 13vPnC Dose 2
percentage of participants13vPnC
Redness: any (n = 122)8.2 (4.0 to 14.6)
Redness: mild (n = 120)6.7 (2.9 to 12.7)
Redness: moderate (n = 117)1.7 (0.2 to 6.0)
Redness: severe (n = 117)1.7 (0.2 to 6.0)
Swelling: any (n = 126)12.7 (7.4 to 19.8)
Swelling: mild (n = 125)12.0 (6.9 to 19.0)
Swelling: moderate (n = 116)0.9 (0.0 to 4.7)
Swelling: severe (n = 117)1.7 (0.2 to 6.0)
Pain: any (n = 237)81.4 (75.9 to 86.2)
Pain: mild (n = 230)78.7 (72.8 to 83.8)
Pain: moderate (n = 150)33.3 (25.9 to 41.5)
Pain: severe (n = 123)8.1 (4.0 to 14.4)
Other pre-specifiedPercentage of Participants Reporting Pre-Specified Local Reactions: 13vPnC Dose 3

Specific local reactions were prompted for each day, and reported using an electronic diary. Redness and Swelling scaled as Any (redness present or swelling present); Mild (2.5 to 5.0 cm); Moderate (5.5 to 10.0 cm); Severe (\>10 cm). Pain scaled as Any (pain present); Mild (awareness of pain; easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating).

Time frame:
Within 14 days post-dose 3
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Pre-Specified Local Reactions: 13vPnC Dose 3
percentage of participants13vPnC
Redness: any (n = 105)9.5 (4.7 to 16.8)
Redness: mild (n = 104)8.7 (4.0 to 15.8)
Redness: moderate (n = 102)3.9 (1.1 to 9.7)
Redness: severe (n = 101)1.0 (0.0 to 5.4)
Swelling: any (n = 107)11.2 (5.9 to 18.8)
Swelling: mild (n = 106)8.5 (4.0 to 15.5)
Swelling: moderate (n = 102)3.9 (1.1 to 9.7)
Swelling: severe (n = 101)1.0 (0.0 to 5.4)
Pain: any (n = 204)81.9 (75.9 to 86.9)
Pain: mild (n = 197)80.2 (73.9 to 85.5)
Pain: moderate (n = 129)30.2 (22.5 to 38.9)
Pain: severe (n = 105)5.7 (2.1 to 12.0)
Other pre-specifiedPercentage of Participants Reporting Pre-Specified Systemic Events: 13vPnC Dose 1

Specific systemic events (fever greater than or equal to \[\>=\]38 degrees Celsius\[C\], fatigue, headache, vomiting, diarrhea, new generalized muscle/joint pain and use of medication to treat pain/fever) were prompted for each day, and reported using an electronic diary. Fatigue, headache, new generalized muscle and joint pain were scaled as: Any (symptom present); Mild (no interference with activity); Moderate (some interference); Severe (prevents routine daily activity). Vomiting was scaled as: Any (vomiting present); Mild (1-2 times in 24 hours \[hrs\]); Moderate (\>2 times in 24 hrs); Severe (requires intravenous hydration). Diarrhea was scaled as: Any (diarrhea present); Mild (2-3 loose stools in 24 hrs); Moderate (4-5 loose stools 24 hrs); Severe (\>=6 loose stools in 24 hrs). Report of fever \>40 degrees C after 13vPnC Dose 1 was confirmed as data entry error.

Time frame:
Within 14 days post-dose 1
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Pre-Specified Systemic Events: 13vPnC Dose 1
percentage of participants13vPnC
Fever >=38 degrees C (n = 162)6.2 (3.0 to 11.1)
Fever >=38, <38.5 degrees C (n = 160)3.8 (1.4 to 8.0)
Fever >=38.5, <39 degrees C (n = 157)1.3 (0.2 to 4.5)
Fever >=39, =<40 degrees C (n = 159)1.3 (0.2 to 4.5)
Fever >40 degrees C (n = 158)0.6 (0.0 to 3.5)
Fatigue: any (n = 235)60.0 (53.4 to 66.3)
Fatigue: mild (n = 223)54.3 (47.5 to 60.9)
Fatigue: moderate (n = 200)37.5 (30.8 to 44.6)
Fatigue: severe (n = 163)6.1 (3.0 to 11.0)
Headache: any (n = 224)61.6 (54.9 to 68.0)
Headache: mild (n = 216)57.4 (50.5 to 64.1)
Headache: moderate (n = 183)31.1 (24.5 to 38.4)
Headache: severe (n = 160)3.1 (1.0 to 7.1)
Vomiting: any (n = 164)11.6 (7.1 to 17.5)
Vomiting: mild (n = 164)11.6 (7.1 to 17.5)
Vomiting: moderate (n = 157)0.0 (0.0 to 2.3)
Vomiting: severe (n = 157)0.0 (0.0 to 2.3)
Diarrhea: any (n = 193)44.0 (36.9 to 51.3)
Diarrhea: mild (n = 191)40.3 (33.3 to 47.6)
Diarrhea: moderate (n = 166)12.7 (8.0 to 18.7)
Diarrhea: severe (n = 160)1.9 (0.4 to 5.4)
New generalized muscle pain: any (n = 234)65.0 (58.5 to 71.1)
New generalized muscle pain: mild (n = 230)60.4 (53.8 to 66.8)
New generalized muscle pain: moderate (n = 183)29.5 (23.0 to 36.7)
New generalized muscle pain: severe (n = 161)3.7 (1.4 to 7.9)
New generalized joint pain: any (n = 193)35.8 (29.0 to 43.0)
New generalized joint pain: mild (n = 185)29.7 (23.2 to 36.9)
New generalized joint pain: moderate (n = 172)19.2 (13.6 to 25.9)
New generalized joint pain: severe (n = 159)1.3 (0.2 to 4.5)
Use of medication to treat pain (n = 185)29.7 (23.2 to 36.9)
Use of medication to treat fever (n = 173)17.3 (12.0 to 23.8)
Other pre-specifiedPercentage of Participants Reporting Pre-Specified Systemic Events: 13vPnC Dose 2

Specific systemic events (fever \>=38 degrees C, fatigue, headache, vomiting, diarrhea, new generalized muscle/joint pain and use of medication to treat pain/fever) were prompted for each day, and reported using an electronic diary. Fatigue, headache, new generalized muscle and joint pain were scaled as: Any (symptom present); Mild (no interference with activity); Moderate (some interference); Severe (prevents routine daily activity). Vomiting was scaled as: Any (vomiting present); Mild (1-2 times in 24 hrs); Moderate (\>2 times in 24 hrs); Severe (requires intravenous hydration). Diarrhea was scaled as: Any (diarrhea present); Mild (2-3 loose stools in 24 hrs); Moderate (4-5 loose stools 24 hrs); Severe (\>=6 loose stools in 24 hrs).

Time frame:
Within 14 days post-dose 2
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Pre-Specified Systemic Events: 13vPnC Dose 2
percentage of participants13vPnC
Fever >=38 degrees C (n = 117)5.1 (1.9 to 10.8)
Fever >=38, <38.5 degrees C (n = 116)4.3 (1.4 to 9.8)
Fever >=38.5, <39 degrees C (n = 116)0.9 (0.0 to 4.7)
Fever >=39, =<40 degrees C (n = 115)0.0 (0.0 to 3.2)
Fever >40 degrees C (n = 115)0.0 (0.0 to 3.2)
Fatigue: any (n = 188)63.3 (56.0 to 70.2)
Fatigue: mild (n = 176)57.4 (49.7 to 64.8)
Fatigue: moderate (n = 154)38.3 (30.6 to 46.5)
Fatigue: severe (n = 121)7.4 (3.5 to 13.7)
Headache: any (n = 173)56.1 (48.3 to 63.6)
Headache: mild (n = 165)48.5 (40.6 to 56.4)
Headache: moderate (n = 142)31.0 (23.5 to 39.3)
Headache: severe (n = 117)3.4 (0.9 to 8.5)
Vomiting: any (n = 120)7.5 (3.5 to 13.8)
Vomiting: mild (n = 119)6.7 (2.9 to 12.8)
Vomiting: moderate (n = 116)0.9 (0.0 to 4.7)
Vomiting: severe (n = 115)0.0 (0.0 to 3.2)
Diarrhea: any (n = 155)44.5 (36.5 to 52.7)
Diarrhea: mild (n = 147)39.5 (31.5 to 47.8)
Diarrhea: moderate (n = 130)15.4 (9.7 to 22.8)
Diarrhea: severe (n = 119)5.0 (1.9 to 10.7)
New generalized muscle pain: any (n = 199)71.9 (65.1 to 78.0)
New generalized muscle pain: mild (n = 188)66.0 (58.7 to 72.7)
New generalized muscle pain: moderate (n = 153)38.6 (30.8 to 46.8)
New generalized muscle pain: severe (n = 125)10.4 (5.7 to 17.1)
New generalized joint pain: any (n = 150)40.0 (32.1 to 48.3)
New generalized joint pain: mild (n = 144)34.7 (27.0 to 43.1)
New generalized joint pain: moderate (n = 135)21.5 (14.9 to 29.4)
New generalized joint pain: severe (n = 119)3.4 (0.9 to 8.4)
Use of medication to treat pain (n = 141)35.5 (27.6 to 44.0)
Use of medication to treat fever (n = 127)18.9 (12.5 to 26.8)
Other pre-specifiedPercentage of Participants Reporting Pre-Specified Systemic Events: 13vPnC Dose 3

Specific systemic events (fever \>=38 degrees C, fatigue, headache, vomiting, diarrhea, new generalized muscle/joint pain and use of medication to treat pain/fever) were prompted for each day, and reported using an electronic diary. Fatigue, headache, new generalized muscle and joint pain were scaled as: Any (symptom present); Mild (no interference with activity); Moderate (some interference); Severe (prevents routine daily activity). Vomiting was scaled as: Any (vomiting present); Mild (1-2 times in 24 hrs); Moderate (\>2 times in 24 hrs); Severe (requires intravenous hydration). Diarrhea was scaled as: Any (diarrhea present); Mild (2-3 loose stools in 24 hrs); Moderate (4-5 loose stools 24 hrs); Severe (\>=6 loose stools in 24 hrs).

Time frame:
Within 14 days post-dose 3
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Pre-Specified Systemic Events: 13vPnC Dose 3
percentage of participants13vPnC
Fever >=38 degrees C (n = 104)7.7 (3.4 to 14.6)
Fever >=38, <38.5 degrees C (n = 104)4.8 (1.6 to 10.9)
Fever >=38.5, <39 degrees C (n = 101)1.0 (0.0 to 5.4)
Fever >=39, =<40 degrees C (n = 101)2.0 (0.2 to 7.0)
Fever >40 degrees C (n = 101)0.0 (0.0 to 3.6)
Fatigue: any (n = 160)56.3 (48.2 to 64.1)
Fatigue: mild (n = 149)48.3 (40.1 to 56.6)
Fatigue: moderate (n = 132)36.4 (28.2 to 45.2)
Fatigue: severe (n = 105)5.7 (2.1 to 12.0)
Headache: any (n = 137)46.7 (38.1 to 55.4)
Headache: mild (n = 130)40.8 (32.2 to 49.7)
Headache: moderate (n = 118)24.6 (17.1 to 33.4)
Headache: severe (n = 103)4.9 (1.6 to 11.0)
Vomiting: any (n = 109)11.0 (5.8 to 18.4)
Vomiting: mild (n = 107)8.4 (3.9 to 15.4)
Vomiting: moderate (n = 104)4.8 (1.6 to 10.9)
Vomiting: severe (n = 101)0.0 (0.0 to 3.6)
Diarrhea: any (n = 134)38.8 (30.5 to 47.6)
Diarrhea: mild (n = 131)35.9 (27.7 to 44.7)
Diarrhea: moderate (n = 109)11.9 (6.5 to 19.5)
Diarrhea: severe (n = 103)1.9 (0.2 to 6.8)
New generalized muscle pain: any (n = 170)65.9 (58.2 to 73.0)
New generalized muscle pain: mild (n = 155)61.3 (53.1 to 69.0)
New generalized muscle pain: moderate (n = 132)31.1 (23.3 to 39.7)
New generalized muscle pain: severe (n = 110)10.0 (5.1 to 17.2)
New generalized joint pain: any (n = 129)31.8 (23.9 to 40.6)
New generalized joint pain: mild (n = 119)26.1 (18.4 to 34.9)
New generalized joint pain: moderate (n = 120)20.0 (13.3 to 28.3)
New generalized joint pain: severe (n = 106)5.7 (2.1 to 11.9)
Use of medication to treat pain (n = 122)32.0 (23.8 to 41.0)
Use of medication to treat fever (n = 118)25.4 (17.9 to 34.3)

Adverse events

Collected over Adverse events (AEs)/serious AEs (SAEs): recorded from signing of informed consent form to completion of study. Participants recorded pre-specified AEs in electronic diary:local reactions; systemic events (up to 14 days after each vaccine dose). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
13vPnC (After Dose 1 and Before Dose 2)—24/329 (7.3%)244/329 (74.2%)
13vPnC (After Dose 2 and Before Dose 3)—14/300 (4.7%)196/300 (65.3%)
13vPnC (After Dose 3 and Before Dose 3 Blood Draw)—4/278 (1.4%)169/278 (60.8%)
13vPnC (After Dose 3 Blood Draw)—10/329 (3%)30/329 (9.1%)
Most frequent serious events
Showing 10 of 51
Most frequent serious events
Event13vPnC (After Dose 1 and Before Dose 2)13vPnC (After Dose 2 and Before Dose 3)13vPnC (After Dose 3 and Before Dose 3 Blood Draw)13vPnC (After Dose 3 Blood Draw)
Coronary artery diseaseCardiac disorders3/3290/3000/2780/329
Angina pectorisCardiac disorders0/3292/3000/2780/329
Non-cardiac chest painGeneral disorders2/3290/3000/2780/329
Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/3291/3000/2782/329
Angina unstableCardiac disorders0/3290/3001/2780/329
PneumoniaInfections and infestations0/3291/3001/2780/329
Alcohol abusePsychiatric disorders1/3290/3001/2781/329
Aortic aneurysmVascular disorders1/3290/3001/2780/329
Prinzmetal anginaCardiac disorders0/3291/3000/2780/329
Erosive oesophagitisGastrointestinal disorders0/3291/3000/2780/329
Most frequent other events
Showing 10 of 299
Most frequent other events
Event13vPnC (After Dose 1 and Before Dose 2)13vPnC (After Dose 2 and Before Dose 3)13vPnC (After Dose 3 and Before Dose 3 Blood Draw)13vPnC (After Dose 3 Blood Draw)
Pain (Any)Skin and subcutaneous tissue disorders205/260193/237167/204—
Pain (Mild)Skin and subcutaneous tissue disorders197/258181/230158/197—
New generalized muscle pain (Any)General disorders152/234143/199112/170—
New generalized muscle pain (Mild)General disorders139/230124/18895/155—
Fatigue (Any)General disorders141/235119/18890/160—
Headache (Any)General disorders138/22497/17364/137—
Headache (Mild)General disorders124/21680/16553/130—
Fatigue (Mild)General disorders121/223101/17672/149—
Diarrhea (Any)General disorders85/19369/15552/134—
Diarrhea (Mild)General disorders77/19158/14747/131—

Baseline characteristics

Safety population included participants who received at least 1 dose of study vaccine.

Age Continuous
Age Continuous(years)13vPnC
Mean47.3 ± 9.10
Sex: Female, Male
Sex: Female, Male(Participants)13vPnC
Female66
Male263
08

Study locations

15 sites
  • Pfizer Investigational Site
    San Francisco, California 94115, United States
  • Pfizer Investigational Site
    Aurora, Colorado 80045, United States
  • Pfizer Investigational Site
    Washington, District of Columbia 20009, United States
  • Pfizer Investigational Site
    Lexington, Kentucky 40536, United States
  • Pfizer Investigational Site
    Springfield, Massachusetts 01199, United States
  • Pfizer Investigational Site
    St. Louis, Missouri 63110, United States
  • Pfizer Investigational Site
    New York, New York 10011, United States
  • Pfizer Investigational Site
    New York, New York 10016, United States
  • Pfizer Investigational Site
    New York, New York 10029, United States
  • Pfizer Investigational Site
    New York, New York 10032, United States
  • Pfizer Investigational Site
    New York, New York 10065, United States
  • Pfizer Investigational Site
    Rochester, New York 14642, United States
  • Pfizer Investigational Site
    Johnson City, Tennessee 37604, United States
  • Pfizer Investigational Site
    Austin, Texas 78705, United States
  • Pfizer Investigational Site
    Dallas, Texas 75246, United States
09

References and documents

Publications

  • Glesby MJ, Watson W, Brinson C, Greenberg RN, Lalezari JP, Skiest D, Sundaraiyer V, Natuk R, Gurtman A, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B. Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in HIV-Infected Adults Previously Vaccinated With Pneumococcal Polysaccharide Vaccine. J Infect Dis. 2015 Jul 1;212(1):18-27. doi: 10.1093/infdis/jiu631. Epub 2014 Nov 13. PubMed 25395187 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2009, a primary completion of May 2012 and a completion of May 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2013, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 20, 2009
First posted
Aug 21, 2009
Start
Nov 2009
Primary completionActual
May 2012
CompletionActual
May 2012
Results first posted
Jun 10, 2013
Last update
Jun 10, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00963235
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Aug 21, 2009
Start date
Nov 2009
Primary completion
May 2012
Completion
May 2012
Results posted
Jun 10, 2013
Last update
Jun 10, 2013

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: 13-valent pneumococcal vaccine

Start the discussion